The management of posttransplant lymphoproliferative disorder

Medical Oncology

Volumn 24, Issue 2, 2007, Pages 125-136

  Frey, Noelle V ^a   Tsai, Donald E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chemotherapy; EBV; Lymphoma; PTLD, rituximab; Transplantation

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ARGININE BUTYRATE; ARGININE DERIVATIVE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA POLYMERASE; DOXORUBICIN; GANCICLOVIR; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; VALACICLOVIR; VINCRISTINE; VIRUS DNA;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER THERAPY; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DISEASE CLASSIFICATION; DNA REPLICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; ERYTHEMA INFECTIOSUM; FOLLICULAR LYMPHOMA; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEPATITIS B; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CYTOKINES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MODELS, BIOLOGICAL; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 36248945074     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02698031     Document Type: Review

References (91)

1. Harris NL SS, Frizzera G, Knowles DM. Post-transplant lymphoproliferative disorders. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 264-269.
2. Paya CV, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517-1525.
3. Yang J, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000;96:4055-4063.
4. Gulley ML, et al. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 2003;76:959-964.
5. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-492.
6. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004;350:1328-1337.
7. Khanna R, Moss DJ, Burrows SR. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999;170:49-64.
8. Callan MF, et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-1402.
9. Epstein MA, Achong BG, Pope JH. Virus in cultured lymphoblasts from a New Guinea Burkitt lymphoma. Br Med J 1967;2:290-291.
10. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989;320:502-506.
11. Curtis RE, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999;94:2208- 2216.
12. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222-230.
13. Herzig KA, et al. A single-centre experience of post-renal transplant lymphoproliferative disorder. Transpl Int 2003;16:529-536.
14. Tsai DE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001;71:1076-1088.
15. Finn L, Reyes J, Bueno J, Yunis E. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 1998;22:299-309.
16. Faller DV, Mentzer SJ, Perrine SP. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 2001;13:360-367.
17. Shapiro RS, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:1234-1243.
18. Darenkov IA, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997;64:848-852.
19. Davis CL, et al. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 1995;9:53-59.
20. Gross TG, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999;23:251-258.
21. Green M, et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000;70:593-596.
22. McDiarmid SV, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998;66:1604-1611.
23. Malouf MA, et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002;21:547-554.
24. Starzl TE, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;1:583-587.
25. Loren AW, Tsai DE. Post-transplant lymphoproliferative disorder. Clin Chest Med 2005;26:631-645, vii.
26. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005;56:155-167.
27. Hurwitz M, et al. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant 2004;8:267-272.
28. Green M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001;1:103-108.
29. Pasquale MA, et al. Burkitt's lymphoma variant of posttransplant lymphoproliferative disease (PTLD). Pathol Oncol Res 2002;8:105- 108.
30. Dotti G, et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000;69:827-833.
31. Leblond V, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998;16:2052-2059.
32. Nelson BP, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000;24:375-385.
33. Dotti G, et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 2002;74:1095-1102.
34. Hauke R, et al. Clinical and pathological features of posttransplant lymphoproliferative disorders: influence on survival and response to treatment. Ann Oncol 2001;12:831-834.
35. Koffman BH, Kennedy AS, Heyman M, Colonna J, Howell C. Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation. Int J Cancer 2000;90:104-109.
36. Elstrom RL, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006;6:569-576.
37. Karras A, et al. Successful renal retransplantation after posttransplant lymphoproliferative disease. Am J Transplant 2004;4:1904-1909.
38. Kang SK, Kirkpatrick JP, Halperin EC. Low-dose radiation for posttransplant lymphoproliferative disorder. Am J Clin Oncol 2003;26:210-214.
39. Swinnen LJ. Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation. Leuk Lymphoma 1997;28:89-101.
40. Mamzer-Bruneel MF, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000;18:3622-3632.
41. Buell JF, et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005; 37: 956-957.
42. Orjuela M, et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9:3945S-3952S.
43. Gross TG. Low-dose chemotherapy for children with posttransplant lymphoproliferative disease. Recent Results Cancer Res 2002;159:96-103.
44. Gross TG, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005;23:6481-6488.
45. Oertel SH, et al. Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol 2003;123:830-835.
46. Komrokji RS, Oliva JL, Zand M, Felgar R, Abboud CN. Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders. Am J Hematol 2005;79:211-215.
47. Bobey NA, Stewart DA, Woodman RC. Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant patient by autologous peripheral blood stem cell transplantation. Leuk Lymphoma 2002;43:2421-2423.
48. Au WY, et al. Treatment of postrenal transplantation lymphoproliferative disease manifesting as plasmacytoma with nonmyeloablative hematopoietic stem cell transplantation from the same kidney donor. Am J Hematol 2003;74:283-286.
49. Faro A, et al. Interferon-alpha affects the immune response in post-transplant lymphoproliferative disorder. Am J Respir Crit Care Med 1996;153:1442-1447.
50. Davis CL et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998;66:1770-1779.
51. Tosato G, Tanner J, Jones KD, Revel M, Pike SE. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 1990;64:3033-3041.
52. Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 1993;91:2806-2814.
53. Haddad E, et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001;97:1590-1597.
54. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91:1644- 1652.
55. Di Gaetano N, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-1587.
56. Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006;19:259-269.
57. McLaughlin P, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
58. Coiffier B, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932.
59. Feugier P, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126.
60. Witzig TE, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005;23:1103-1108.
61. Hiddemann W, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732.
62. Choquet S, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053-3057.
63. Milpied N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11 Suppl 1:113-116.
64. Oertel SH, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901-2906.
65. Faye A et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001;115:112-118.
66. van Esser JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364- 4369.
67. Webber S, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory PTLD after pediatric solid organ transplantation: multicenter experience and from a registry and prospective clinical trial. Blood 2004;104.
68. Gonzalez-Barca E, et al. First-line treatment with rituximab improves survival of patients with post transplant lymphoproliferative disorder. Blood 2004;104.
69. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-473.
70. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-69.
71. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000;96:1184-1186.
72. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a posttransplantation lymphoproliferative disorder. N Engl J Med 2001;345:1000.
73. Savoldo B, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for posttransplant lymphoproliferative disease. Am J Transplant 2005;5:566-572.
74. Papadopoulos EB, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
75. O'Reilly RJ, et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997;157:195-216.
76. Rooney CM, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
77. Gottschalk S, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001;97:835-843.
78. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005;56:29-44.
79. Nalesnik MA, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997;63:1200-1205.
80. Comoli P, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBVrelated lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002;99:2592-2598.
81. Comoli P, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005;5:1415-1422.
82. Haque T, et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 1998;160:6204-6209.
83. Khanna R, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999;96:10391-10396.
84. Sherritt MA, et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 2003;75:1556-1560.
85. Metes D, et al. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals. Transplantation 2000;70:1507-1515.
86. Popescu I, et al. Ex vivo priming of naive T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. Am J Transplant 2003;3:1369-1377.
87. Haque T, et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360:436-442.
88. Sun Q, Burton R, Reddy V, Lucas KG. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol 2002;118:799-808.
89. Emanuel DJ, et al. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 1997;63:1691-1694.
90. Restrepo A, et al. Post-liver transplantation lymphoproliferative disorders with and without infusions of donor bone marrow cells. Crit Rev Oncog 1999;10:239-245.
91. Wilkie GM, et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases. J Immunother 2004;27:309-316.